Bariatric treatments for adult obesity - Institute of Health Economics

More documents

Recommendations

Info

15. Lacey LA, Wolf A, O'shea D, Erny S, Ruof J. Cost-effectiveness of orlistat for the treatmentof overweight and obese patients in Ireland. International Journal of Obesity 2005;29(8):975-82.16. Iannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment with orlistat in Italianobese patients. Current Medical Research and Opinion 2008;24(1):63-74.17. Hampp C, Hartzema AG, Kauf TL. Cost-utility analysis of rimonabant in the treatment ofobesity. Value Health 2008;11(3):389-99.18. Brennan A, Ara R, Sterz R, Matiba B, Bergemann R. Assessment of clinical and economicbenefits of weight management with sibutramine in general practice in Germany. EuropeanJournal of Health Economics 2006;7(4):276-84.19. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment ofobesity. Medical Decision Making 2004;24(1):9-19.20. Ara R, Brennan A. The cost-effectiveness of sibutramine in non-diabetic obese patients:evidence from four Western countries. Obesity Reviews 2007;8(4):363-71.21. Roux L, Kuntz KM, Donaldson C, Goldie SJ. Economic evaluation of weight lossinterventions in overweight and obese women. Obesity 2006;14(6):1093-1106.22. Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A. Orlistat in responding obese type 2diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursementin Sweden and Switzerland. International Journal of Obesity 2005;29(5):517-23.23. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J. A health economic model toassess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.Diabetes Care 2002;25(2):303-8.24. Malone DC, Raebel MA, Porter JA, Lanty FA, Conner DA, Gay EC, et al. Cost-effectivenessof sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-losstherapy within a weight management program. Journal of Managed Care Pharmacy 2005;11(6):458-68.25. Gustafson A, Khavjou O, Stearns SC, Keyserling TC, Gizlice Z, Lindsley S, et al. Costeffectivenessof a behavioral weight loss intervention for low-income women: the Weight-Wise Program. Preventive Medicine 2009;49(5):390-5.26. Gusi N, Reyes MC, Gonzalez-Guerrero JL, Herrera E, Garcia JM. Cost-utility of a walkingprogram for moderately depressed, obese, or overweight elderly women in primary care: arandomised controlled trial. BMC Public Health 2008;8:231.27. Bemelmans W. The costs, effects and cost-effectiveness of counteracting overweight on apopulation level. A scientific base for policy targets for the Dutch national plan for action.Preventive Medicine 2008;46(2):127-32.28. Olsen J, Willaing I, Ladelund S, Jorgensen T, Gundgaard J, Sorensen J. Cost-effectiveness ofnutritional counseling for obese patients and patients at risk of ischemic heart disease.International Journal of Technology Assessment in Health Care 2005;21(2):194-202.29. Tsai AG, Glick HA, Shera D, Stern L, Samaha FF. Cost-effectiveness of a low-carbohydratediet and a standard diet in severe obesity. Obesity Research 2005;13(10):1834-40.Bariatric treatments for adult obesity 202
30. Sevick MA, Miller GD, Loeser RF, Williamson JD, Messier SP. Cost-effectiveness of exerciseand diet in overweight and obese adults with knee osteoarthritis. Medicine and Science in Sportsand Exercise 2009;41(6):1167-74.31. Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and health effects of lifestyleintervention in the prevention and treatment of obesity in Switzerland. International Journal ofPublic Health 2007;52(6):372-82.32. Zingmond DS, McGory ML, Ko CY. Hospitalization before and after gastric bypass surgery.The Journal of the American Medical Association 2005;294(15):1918-24.33. Sampalis J, Liberman M, Auger S, Christou N. The impact of weight reduction surgery onhealth-care costs in morbidly obese patients. Obesity Surgery 2004;14(7):939-47.Bariatric treatments for adult obesity 203
Page 1 and 2:
Alberta STE ReportBariatric treatme
Page 3 and 4:
Alberta STE ReportBariatric treatme
Page 5 and 6:
EXECUTIVE SUMMARYSocial and System
Page 7 and 8:
Three surgical procedures—adjusta
Page 9:
Costs of Bariatric Surgery and Pote
Page 12 and 13:
Regulatory status .................
Page 14 and 15:
TABLES AND FIGURESSection One: Soci
Page 16 and 17:
ABBREVIATIONSAll abbreviations that
Page 18 and 19:
LYMmMAMDMUHCNANHLBINHSNICENIHNNHNPH
Page 20 and 21:
Bariatric physician: a licensed Doc
Page 22 and 23:
High-density lipoprotein (HDL): a f
Page 24 and 25:
Very-low-calorie diet (VLCD): a die
Page 26 and 27:
Additional Internet searches were c
Page 28 and 29:
This report addresses obesity in ad
Page 30 and 31:
Many systemic factors have been ide
Page 32 and 33:
Severe obesity is associated with d
Page 34 and 35:
eport their height and under-report
Page 36 and 37:
Also using self-reported data from
Page 38 and 39:
An examination of overall obesity d
Page 40 and 41:
Table S.2 presents the associationa
Page 42 and 43:
• have multiple focal points and
Page 45 and 46:
The main problem in any weight mana
Page 47:
food, and a negative body image. As
Page 50 and 51:
directly causes death. 61 To the ex
Page 52 and 53:
The addition of a selected pharmaco
Page 54 and 55:
lack of formal training in nutritio
Page 56 and 57:
slightly more likely to have prescr
Page 58 and 59:
selection criteria, have facilities
Page 60 and 61:
Barriers to using appropriate baria
Page 62 and 63:
Overview of adult obesityOver the p
Page 64 and 65:
the need for regular physical activ
Page 66 and 67:
phenylpropanolamine/25. Sibutramine
Page 68 and 69:
Complianceand AdherenceDemand andut
Page 70 and 71:
Aetna Clinical PolicyBulletinswww.a
Page 72 and 73:
Overweight 123,821 172,971 157,623
Page 74 and 75:
REFERENCES1. 2006 Canadian clinical
Page 76 and 77:
34. Gostin LO. Fast and supersized:
Page 78 and 79:
69. Klarenbach S, Padwal R, Wiebe N
Page 80 and 81:
105. Hill JO, Thompson H, Wyatt H.
Page 82 and 83:
141. Ross R, Bradshaw AJ. The futur
Page 84 and 85:
172. Arkinson J, Ji H, Fallah S, Pe
Page 86 and 87:
This section will address a set of
Page 88 and 89:
dietary therapy is to reduce total
Page 90 and 91:
Additional benefits of exercise ove
Page 92 and 93:
medications that inhibit intestinal
Page 94 and 95:
Rimonabant may be considered for pa
Page 96 and 97:
Long-term complications are specifi
Page 98 and 99:
Devices used for bariatric surgeryH
Page 100 and 101:
Description of the Included Systema
Page 102 and 103:
AEs for sibutramineAs compared to a
Page 104 and 105:
Evidence on Efficacy/EffectivenessW
Page 106 and 107:
Table T.7: Effects of behavioural t
Page 108 and 109:
SurgeryDescription of the included
Page 110 and 111:
follow-up time was 3 years. Results
Page 112 and 113:
group as compared to the VBG group.
Page 114 and 115:
The authors identified many methodo
Page 116 and 117:
The investigators pointed out that
Page 118 and 119:
approximately 3 to 5 kilograms. For
Page 120 and 121:
for studies with a mean age of part
Page 122 and 123:
Examining whether use of any of the
Page 124 and 125:
Evidence from placebo-controlled cl
Page 126 and 127:
colorectal or gastroesophageal or f
Page 128 and 129:
Web of ScienceISI Interface License
Page 130 and 131:
AMA Clinical PracticeGuidelineswww.
Page 132 and 133:
critical appraisal of the included
Page 134 and 135:
APPENDIX T.B: EXCLUDED STUDIESTable
Page 136 and 137:
Padwal R, Li SK, Lau DC. Long-term
Page 138 and 139:
Quality subsection 1: At least MEDL
Page 140 and 141:
Quality subsection 5a:Study quality
Page 142 and 143:
Partially reported: The study types
Page 144 and 145:
Table T.C.1: Results of quality ass
Page 146 and 147:
Table T.C.1: Results of quality ass
Page 148 and 149:
APPENDIX T.D: CHARACTERISTICS OF SY
Page 150 and 151:
Table T.D.1: Characteristics of the
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
APPENDIX T.E: EVIDENCE TABLE ON SAF
Page 158 and 159:
Serious surgical complicationsSurgi
Page 160 and 161:
LSGmMAMDNAnssORQoLRCTRDRRRYGBSBPTGV
Page 162 and 163:
Table T.F.1-2: Weight loss - Behavi
Page 164 and 165:
Table T.F.1-4: Weight loss - Surger
Page 166 and 167:
Table T.F.2: Quality of life (QoL)
Page 168 and 169:
Curioni & Lourenco 2005 58Cholester
Page 170 and 171:
Table T.F.3-3: Risk factors/comorbi
Page 172 and 173:
Table T.F.3-5: Long-term effects of
Page 174 and 175:
Maciejewski et al., 2005 65Avenell
Page 176 and 177: Table T.G.2: Effects of bariatric s
Page 178 and 179: Table T.G.4: Effects of bariatric s
Page 180 and 181: 18. Cerulli J, Lomaestro BM, Malone
Page 182 and 183: 50. Health Canada Drug Product Data
Page 184 and 185: SECTION THREE: ECONOMIC EVALUATIONC
Page 186 and 187: Definition of bariatric surgical pa
Page 188 and 189: etween surgical interventions, the
Page 190 and 191: concluded that adding orlistat to L
Page 192 and 193: Weight management program (WMP) ver
Page 194 and 195: groups. Compared with standard care
Page 196 and 197: Results from Analysis of Provincial
Page 198 and 199: DiscussionThe objectives of the eco
Page 200 and 201: surgical suites, and so on. The bud
Page 202 and 203: APPENDIX E.A: LITERATURE SEARCH SUM
Page 204 and 205: CRD Databases(DARE, HTA & NHS EED)h
Page 206 and 207: Web of ScienceISI Interface License
Page 208 and 209: NEOS Librarywww.library.ualberta.ca
Page 210 and 211: Table E.A.2: Evidence table of revi
Page 212 and 213: ResultHealth outcomesCostsMarginal
Page 214 and 215: CostsMarginal analysisThe cost anal
Page 216 and 217: Time Horizon/discount rateCurrency/
Page 218 and 219: Objectivestudy perspective: society
Page 224 and 225: S4Economic burden of obesityMean co
Page 228 and 229: Author Contribution StatementsPaula
show all

Bariatric treatments for adult obesity - Institute of Health Economics

Create successful ePaper yourself

Delete template?

Save as template?